Join our innovative Phase 2 clinical trial evaluating Halneuron—a promising, investigational treatment for those suffering from Chemotherapy-Induced Neuropathic Pain (CINP).
Those who qualify and choose to participate will be compensated up to $500 for 10 visits over approximately 4 weeks.
This clinical study is designed to see how well the study drug, Halneuron, helps to reduce pain and improve the quality of life for adults suffering from CINP compared to a placebo. The study will also look at how safe and tolerable the drug is.
If you qualify and choose to participate, there is a 50% chance you will receive the study drug and a 50% chance you will receive a placebo. A placebo is an inactive material that looks like Halneuron but does not contain any active study drug.
You will be on this study for approximately 4 weeks which will include a screening period, a treatment period, and a study completion visit. The study will require up to 10 in-clinic visits. If you qualify and choose to participate, you will be compensated up to $500 for your study-related time and travel. Your participation is entirely voluntary, and you can leave the study at any time.
Those who qualify and choose to participate could receive:
Access to the study drug, Halneuron, at no cost
Access to our top-tier team of board-certified physicians at no cost
Compensation up to $500 for 10 visits over 4 weeks
A research study or clinical trial is the process a potential new drug, device, procedure, or process goes through to prove that it is safe, tolerable and effective for the condition it is being studied for. Research studies are the only way to advance medicine for future generations.
Adults diagnosed with Chemotherapy-Induced Neuropathic Pain following platinum or taxane chemotherapy may be eligible for participation. Patients from all backgrounds and walks of life are encouraged to participate.
Halneuron is an investigational study drug designed to target specific sodium channels, aiming to reduce neuropathic pain symptoms.
Participants will receive 8 injections over a 14-day period, followed by a 28-day safety and effectiveness evaluation.
Every participant in every research study must go through the informed consent process. During this, the trial doctor and research team go over what will happen in the study, what treatments you might get, how long the trial is expected to last, what happens during visits, the potential risks and benefits, and many other important facts about the study. Participants may withdraw their consent and discontinue the study at any time for any reason.
A placebo looks like a treatment but does not have any active medicine in it. Researchers use placebos to help make sure any changes in the participants’ health are actually caused by the study treatment. You do not get to choose if you get the study treatment or the placebo, and you may not know if you get the placebo until after the study. Not all research studies use a placebo.
If studies do not include diverse participants, we cannot know if treatments work for everyone who needs them. Studies only tell researchers how something works for the participants of that study, and they may not work the same in people of different races, ethnicities, ages, or sexes.
All research studies must follow federal laws and ethical guidelines, including HIPAA. Studies must also be approved by an expert group called an institutional review board (IRB) that helps make sure the trial is fair and as safe as possible, and that any risks to the participants are worth the potential benefits.